Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage
Overview
Endocrinology
Authors
Affiliations
Objective: Mitochondrial damage contributes to extracellular matrix (ECM) deposition and renal fibrosis. In this study, we aimed (1) to investigate whether fluorofenidone (AKF-PD) can attenuate mitochondrial damage in two renal fibrosis models: unilateral ureteral obstruction (UUO) and renal ischemia-reperfusion injury (IRI), and (2) to explore the underlying mechanism.
Method: Mitochondrial damage and renal lesions were analyzed in the UUO and IRI models. Mitochondrial energy metabolism, mitochondrial biogenesis, and oxidative stress were measured to assess the effect of AKF-PD on mitochondrial damage and to explore the underlying mechanism. In addition, HK-2 cells were stimulated with TGF- with and without AKF-PD. The mitochondrial morphology, mtROS, ATP contents, and redox-related proteins were then examined.
Results: In both UUO and IRI models, AKF-PD relieved renal fibrosis, maintained mitochondrial structure, and increased mitochondrial DNA copy numbers. The protection was associated with (1) sustaining mitochondrial energy metabolism, evident by elevations of tricarboxylic acid (TCA) cycle enzymes and mitochondrial respiratory chain complexes; (2) improving mitochondrial biogenesis with increases of TFAM, NRF1, PGC-1, and SIRT1; and (3) reducing mitochondrial oxidative stress likely via regulating SOD2, SIRT3, and NOX4 expressions. In HK-2 cells treated with TGF-, AKF-PD protected mitochondria along with improving mitochondrial morphology, enhancing ATP production, reducing mtROS, and regulating SOD2, SIRT3, and NOX4 expression.
Conclusion: We demonstrate that AKF-PD inhibited renal fibrosis at least in part via protecting mitochondria from damages developed in the UUO and IRI models. The mitochondrial protection was associated with sustaining mitochondrial energy metabolism, improving mitochondrial biogenesis, and reducing mitochondrial oxidative stress. This research verified the protective effect of AKF-PD on mitochondria in the UUO and IRI models and elaborated the underlying mechanism.
ADAMTS13 attenuates renal fibrosis by suppressing thrombospondin 1 mediated TGF-β1/Smad3 activation.
Guo J, Zhou S, Wang H, Qiu X, Dong F, Jiang S Toxicol Appl Pharmacol. 2025; 496:117260.
PMID: 39929281 PMC: 11877307. DOI: 10.1016/j.taap.2025.117260.
Tasic D, Dimitrijevic Z Diagnostics (Basel). 2024; 14(18).
PMID: 39335773 PMC: 11431490. DOI: 10.3390/diagnostics14182094.
Wang B, Yang Q, Che L, Sun L, Du N Aging (Albany NY). 2024; 16(16):11877-11892.
PMID: 39172111 PMC: 11386924. DOI: 10.18632/aging.206054.
Feng W, Zhu N, Xia Y, Huang Z, Hu J, Guo Z iScience. 2024; 27(4):109504.
PMID: 38632989 PMC: 11022057. DOI: 10.1016/j.isci.2024.109504.
Mitochondrial metabolism and targeted treatment strategies in ischemic-induced acute kidney injury.
Chen Y, Li Z, Zhang H, Chen H, Hao J, Liu H Cell Death Discov. 2024; 10(1):69.
PMID: 38341438 PMC: 10858869. DOI: 10.1038/s41420-024-01843-5.